Breast Cancer Survival and Survival Gap Apportionment in Sub-Saharan Africa: African Breast Cancer – Disparities in Outcomes ABC-DO Cohort

2019 ◽  
Author(s):  
Valerie Mccormack ◽  
Fiona McKenzie ◽  
Milena Foerster ◽  
Annelle Zietsman ◽  
Moses Galukande ◽  
...  
2020 ◽  
Vol 8 (9) ◽  
pp. e1203-e1212 ◽  
Author(s):  
Valerie McCormack ◽  
Fiona McKenzie ◽  
Milena Foerster ◽  
Annelle Zietsman ◽  
Moses Galukande ◽  
...  

2019 ◽  
Vol 146 (5) ◽  
pp. 1208-1218 ◽  
Author(s):  
Walburga Y. Joko‐Fru ◽  
Adalberto Miranda‐Filho ◽  
Isabelle Soerjomataram ◽  
Marcel Egue ◽  
Marie‐Therese Akele‐Akpo ◽  
...  

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Pauline Boucheron ◽  
Angelica Anele ◽  
Annelle Zietsman ◽  
Moses Galukande ◽  
Groesbeck Parham ◽  
...  

Abstract Background Arm and shoulder problems (ASP), including lymphedema, were common among women with breast cancer in high-income countries before sentinel lymph node biopsy became the standard of care. Although ASP impair quality of life, as they affect daily life activities, their frequency and determinants in Sub-Saharan Africa remain unclear. Methods All women newly diagnosed with breast cancer at the Namibian, Ugandan, Nigerian, and Zambian sites of the African Breast Cancer-Disparities in Outcomes (ABC-DO) cohort study were included. At each 3-month follow-up interview, women answered the EORTC-QLQ-Br23 questionnaire, including three ASP items: shoulder/arm pain, arm stiffness, and arm/hand swelling. We estimated the cumulative incidence of first self-reported ASP, overall and stratified by study and treatment status, with deaths treated as competing events. To identify determinants of ASP, we estimated cause-specific hazard ratios using Cox models stratified by study site. Results Among 1476 women, up to 4 years after diagnosis, 43% (95% CI 40–46), 36% (33–38) and 23% (20–25), respectively, self-reported having experienced arm/shoulder pain, stiffness and arm/hand swelling at least once. Although risks of self-reported ASP differed between sites, a more advanced breast cancer stage at diagnosis, having a lower socioeconomic position and receiving treatment increased the risk of reporting an ASP. Conclusion ASP are very common in breast cancer survivors in Sub-Saharan Africa. They are influenced by different factors than those observed in high-income countries. There is a need to raise awareness and improve management of ASP within the African setting.


2018 ◽  
Vol 29 (8) ◽  
pp. 721-730 ◽  
Author(s):  
Fiona McKenzie ◽  
Annelle Zietsman ◽  
Moses Galukande ◽  
Angelica Anele ◽  
Charles Adisa ◽  
...  

2020 ◽  
Vol 189 (10) ◽  
pp. 1185-1196 ◽  
Author(s):  
Milena Foerster ◽  
Angelica Anele ◽  
Charles Adisa ◽  
Moses Galukande ◽  
Groesbeck Parham ◽  
...  

Abstract Accurate survival estimates are needed for guiding cancer control efforts in sub-Saharan Africa, but previous studies have been hampered by unknown biases due to excessive loss to follow-up (LTFU). In the African Breast Cancer—Disparities in Outcomes Study, a prospective breast cancer cohort study, we implemented active mobile health follow-up, telephoning each woman or her next-of-kin (NOK) trimonthly on her mobile phone to update information on her vital status. Dates of every contact with women/NOK were analyzed from diagnosis in 2014–2017 to the earliest of September 1, 2018, death, or 3 years postdiagnosis. The cumulative incidence of being LTFU was calculated considering deaths as competing events. In all, 1,490 women were followed for a median of 24.2 (interquartile range (IQR), 14.2–34.5) months, corresponding to 8,529 successful contacts (77% of total contacts) with the women/NOK. Median time between successful contacts was 3.0 (IQR, 3.0–3.7) months. In all, 71 women (5.3%) were LTFU at 3 years: 0.8% in Nigeria, 2.2% in Namibia, and 5.6% in Uganda. Because of temporary discontinuity of active follow-up, 20.3% of women were LTFU after 2 years in Zambia. The median time to study notification of a death was 9.1 (IQR, 3.9–14.0) weeks. Although the present study was not a randomized controlled trial, in this cancer cohort with active mobile health follow-up, LTFU was much lower than in previous studies and enabled estimation of up-to-date and reliable cancer survival.


Sign in / Sign up

Export Citation Format

Share Document